Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r

SELECT-EARLY results for #upadacitinib in #RA 👉🏼UPA better than MTX for clinical response and remission 👉🏼⬆️rates of HZ, neutropenia, CPK elevations 👉🏼No new safety risks identified Abs#1692 #ACR21 @RheumNow https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0

• Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthr…

The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis Dr. Richard Conway ( @RichardPAConway) reviews an abstract presented at #ACR21. https://t.co/PkJmpODz8v https://t.co/zuJjofka3B

• https://bit.ly/31v9wVd

Adults with #JIA #uveitis are still affected into adulthood. @Mara_Becker discusses visual outcomes #ACR21 https://t.co/ZBjw1CfSmv

Prof. Cornelia Weyand wonderfully summarizes the mechanisms behind the premature immune #aging phenotype in #RheumatoidArthritis leading to tissue #Inflammation 🔸defect in mitoDNA repair 🔸expanded rough ER 🔸⬇ protein myristoylation @RheumNow #ACR21 #RheumTwitter https://t.co/8cyqLscctB

Can you stop monitoring eyes in + ANA and/or pauciarticular pt who becomes an adult if no uveitis ever, in last 5 yrs, etc. When can we stop looking? #AVR21 @RheumNow https://t.co/1Ml1BuJD7Y

• Sheila Angeles-Han on Twitter: "Adults with #JIA #uveitis are still affect…

#ACR21 Year In Review highlighted the need to combat the root causes of socioeconomic disparities to improve functional status in #rheumatoid #arthritis @RheumNow https://t.co/MKgh7UEP8b https://t.co/Vg2jyfuDnf

• Socioeconomic Disparities in Functional Status in a National Sample of Patients…